Lumentum Shares Rise 2% in After-Hours Trading, EchoStar Jumps 4%; S&P Dow Jones Announces Inclusion in S&P 500
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy LITE?
Source: moomoo
Market Performance: Shares of Lumen Technologies have increased by 2% in extended trading, while EchoStar's shares rose by 4%.
S&P Dow Jones Update: S&P Dow Jones Indices has announced that Lumen Technologies will be joining the S&P 500 index.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LITE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LITE
Wall Street analysts forecast LITE stock price to fall
14 Analyst Rating
9 Buy
5 Hold
0 Sell
Moderate Buy
Current: 558.440
Low
147.00
Averages
303.36
High
470.00
Current: 558.440
Low
147.00
Averages
303.36
High
470.00
About LITE
Lumentum Holdings Inc. is a designer and manufacturer of optical and photonic products enabling optical networking and laser applications worldwide. Its segments include Cloud & Networking and Industrial Tech. The Cloud & Networking segment products include a comprehensive portfolio of optical and photonic components, modules, and subsystems supplied to cloud and communications network operators and network equipment manufacturers building cloud data center infrastructure, including products for artificial intelligence and machine learning (AI/ML) and data center interconnect (DCI) applications, and communications service provider networks, including products for access (local), metro (intracity), long-haul (city-to-city and worldwide), and submarine (undersea) network infrastructure. The Industrial Tech segment products include solid-state lasers, kilowatt-class fiber lasers, diode lasers, ultrafast lasers, and gas lasers, which address applications in numerous end-markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Oil Price Surge Drives Significant Stock Movements
- Oil Price Impact: Oil prices surged past $110 per barrel due to the ongoing Iran conflict, leading Chevron to hit an all-time high, while Talos Energy rose by 5%, and ConocoPhillips and Northern Oil gained 2% and 3% respectively, indicating strong performance among oil companies in a high-price environment.
- Hims & Hers Health Surge: The company's stock soared 39% after striking a deal with Novo Nordisk to sell its weight-loss drug, resolving a lawsuit over a copycat version, which is expected to significantly enhance its market share and brand reputation.
- Live Nation Settlement Near: Live Nation's shares rose 6% as it nears a settlement with the Department of Justice regarding monopoly allegations in the live concert industry, which, if successful, will stabilize and expand its future business operations.
- United Therapeutics Buyback Plan: The pharmaceutical company's shares increased by over 8% after its board authorized a $2 billion stock repurchase plan, with $1.5 billion allocated for accelerated buybacks, which is expected to boost investor confidence and enhance shareholder value.
See More
Middle East Tensions Impact Global Markets
- Market Decline: Wall Street opened the week in negative territory, with the S&P 500 falling 0.5% to around 6,700 points, reflecting investor concerns over Middle East tensions that could lead to increased market volatility.
- Rising Oil Prices: WTI crude oil surged about 6% to $97 per barrel, while Brent climbed to $98.31, although both benchmarks trimmed larger overnight gains in futures trading, indicating heightened worries over potential supply disruptions.
- Policy Response Expectations: U.S. President Trump is expected to announce measures to ease surging oil prices, including a coordinated release of strategic petroleum reserves by G7 countries, highlighting the seriousness with which major economies are addressing the risk of prolonged supply disruptions.
- Escalating Geopolitical Tensions: NATO intercepted an Iranian ballistic missile heading toward Turkey on Monday, signaling rising concerns that the regional conflict could expand, further increasing market uncertainty.
See More
Relmada Therapeutics Shares Surge 40.8% on Promising Trial Data
- Market Decline: U.S. stocks fell broadly on Monday, with the Dow Jones index dropping around 650 points, indicating investor concerns about economic outlook which may impact consumer spending and overall market confidence.
- Relmada Stock Surge: Shares of Relmada Therapeutics Inc. soared 40.8% to $6.27 during Monday's session, driven by the release of promising interim data from its Phase 2 trial of NDV-01 for treating non-muscle invasive bladder cancer.
- Clinical Trial Results: The 12-month interim data revealed a complete response rate of 76%, with an impressive 80% in the BCG-unresponsive patient population, providing strong support for Relmada's treatment approach and potentially enhancing market acceptance.
- Positive Market Reaction: The favorable feedback from clinical data has led to optimistic investor sentiment regarding Relmada's future prospects, not only boosting the company's stock price but also likely attracting more investor interest in its ongoing research and development efforts.
See More
Vertiv and Two Other New S&P 500 Members Resist Stock Market Decline Amid Iran Concerns
- Market Reaction: Three stocks set to join the S&P 500 experienced a rally on Monday despite a broader market slump.
- Oil Prices Surge: The rally occurred amid rising oil prices, which surpassed $100 a barrel due to the ongoing Iran war.
See More
Vertiv Shares Surge: The Impact of Joining the S&P 500 Outweighs the Iran Conflict.
- Market Reaction: Three stocks set to join the S&P 500 experienced a rally on Monday despite a broader market slump.
- Oil Prices Surge: The rally occurred amid rising oil prices, which surpassed $100 a barrel due to the ongoing conflict in Iran.
See More
Ten Large-Cap Stocks with Worst Performance Last Week
- Lumentum Holdings Decline: Lumentum Holdings Inc. saw a 24.65% drop this week, despite its upcoming inclusion in the S&P 500 on March 23, 2026, indicating a significant loss of investor confidence in its future performance.
- Celsius Holdings Struggles: Celsius Holdings, Inc. experienced a 17.86% decline this week, reflecting investor concerns over its profitability, particularly in a challenging overall market environment.
- Pressure on Precious Metals: First Majestic Silver Corp. dropped 17.69% this week, as rising dollar strength and yields exerted greater market pressure on precious metal companies amid escalating conflict in the Middle East.
- Carnival Corporation Impacted: Carnival Corporation's stock fell 10.45% this week, as coordinated U.S. and Israeli strikes on Iranian targets heightened geopolitical risks, leading to diminished investor confidence in cruise operators.
See More
Oil Price Surge Drives Significant Stock Movements
- Oil Price Impact: Oil prices surged past $110 per barrel due to the ongoing Iran conflict, leading Chevron to hit an all-time high, while Talos Energy rose by 5%, and ConocoPhillips and Northern Oil gained 2% and 3% respectively, indicating strong performance among oil companies in a high-price environment.
- Hims & Hers Health Surge: The company's stock soared 39% after striking a deal with Novo Nordisk to sell its weight-loss drug, resolving a lawsuit over a copycat version, which is expected to significantly enhance its market share and brand reputation.
- Live Nation Settlement Near: Live Nation's shares rose 6% as it nears a settlement with the Department of Justice regarding monopoly allegations in the live concert industry, which, if successful, will stabilize and expand its future business operations.
- United Therapeutics Buyback Plan: The pharmaceutical company's shares increased by over 8% after its board authorized a $2 billion stock repurchase plan, with $1.5 billion allocated for accelerated buybacks, which is expected to boost investor confidence and enhance shareholder value.
See More
Middle East Tensions Impact Global Markets
- Market Decline: Wall Street opened the week in negative territory, with the S&P 500 falling 0.5% to around 6,700 points, reflecting investor concerns over Middle East tensions that could lead to increased market volatility.
- Rising Oil Prices: WTI crude oil surged about 6% to $97 per barrel, while Brent climbed to $98.31, although both benchmarks trimmed larger overnight gains in futures trading, indicating heightened worries over potential supply disruptions.
- Policy Response Expectations: U.S. President Trump is expected to announce measures to ease surging oil prices, including a coordinated release of strategic petroleum reserves by G7 countries, highlighting the seriousness with which major economies are addressing the risk of prolonged supply disruptions.
- Escalating Geopolitical Tensions: NATO intercepted an Iranian ballistic missile heading toward Turkey on Monday, signaling rising concerns that the regional conflict could expand, further increasing market uncertainty.
See More
Relmada Therapeutics Shares Surge 40.8% on Promising Trial Data
- Market Decline: U.S. stocks fell broadly on Monday, with the Dow Jones index dropping around 650 points, indicating investor concerns about economic outlook which may impact consumer spending and overall market confidence.
- Relmada Stock Surge: Shares of Relmada Therapeutics Inc. soared 40.8% to $6.27 during Monday's session, driven by the release of promising interim data from its Phase 2 trial of NDV-01 for treating non-muscle invasive bladder cancer.
- Clinical Trial Results: The 12-month interim data revealed a complete response rate of 76%, with an impressive 80% in the BCG-unresponsive patient population, providing strong support for Relmada's treatment approach and potentially enhancing market acceptance.
- Positive Market Reaction: The favorable feedback from clinical data has led to optimistic investor sentiment regarding Relmada's future prospects, not only boosting the company's stock price but also likely attracting more investor interest in its ongoing research and development efforts.
See More
Vertiv and Two Other New S&P 500 Members Resist Stock Market Decline Amid Iran Concerns
- Market Reaction: Three stocks set to join the S&P 500 experienced a rally on Monday despite a broader market slump.
- Oil Prices Surge: The rally occurred amid rising oil prices, which surpassed $100 a barrel due to the ongoing Iran war.
See More
Vertiv Shares Surge: The Impact of Joining the S&P 500 Outweighs the Iran Conflict.
- Market Reaction: Three stocks set to join the S&P 500 experienced a rally on Monday despite a broader market slump.
- Oil Prices Surge: The rally occurred amid rising oil prices, which surpassed $100 a barrel due to the ongoing conflict in Iran.
See More
Ten Large-Cap Stocks with Worst Performance Last Week
- Lumentum Holdings Decline: Lumentum Holdings Inc. saw a 24.65% drop this week, despite its upcoming inclusion in the S&P 500 on March 23, 2026, indicating a significant loss of investor confidence in its future performance.
- Celsius Holdings Struggles: Celsius Holdings, Inc. experienced a 17.86% decline this week, reflecting investor concerns over its profitability, particularly in a challenging overall market environment.
- Pressure on Precious Metals: First Majestic Silver Corp. dropped 17.69% this week, as rising dollar strength and yields exerted greater market pressure on precious metal companies amid escalating conflict in the Middle East.
- Carnival Corporation Impacted: Carnival Corporation's stock fell 10.45% this week, as coordinated U.S. and Israeli strikes on Iranian targets heightened geopolitical risks, leading to diminished investor confidence in cruise operators.
See More
